Strides Pharma Science share news, announcements and annual reports
NSE: STARBSE: 532531Pharmaceuticals & BiotechnologySmall Cap
Strides Pharma Science Limited · Formerly Strides Shasun · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Feb 2000 on NSE, Jun 2004 on BSE
Last close ₹1,068.80down ₹28.70 (2.62%)BSE ₹1,069.15
Share price at the NSE close on 30 Oct 2026. Previous close ₹1,097.50.
30 Oct: open ₹1,050.00, high ₹1,076.90, low ₹972.00
52-week range of traded prices to 30 Oct 2026
₹768.65Low, 29 Jan 2026₹1,260.90High, 21 Sep 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹9,851 Cr580th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 15.97
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 2.88
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.47%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 20.0%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 13.9%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Sep 2026.
- 0.53
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 26,77,98551.0% delivered
Strides Pharma Science board meetings
114 filed, newest first. Page 2 of 3.
Oct 2018
Jul 2018
May 2018
18 May · Board meeting
18 May · Board meeting
18 May · Board meeting
Feb 2018
Oct 2017
31 Oct · Board meeting
31 Oct · Board meeting
Aug 2017
Jun 2017
19 Jun · Board meeting
May 2017
18 May · Board meeting
18 May · Board meeting
Jan 2017
Oct 2016
Aug 2016
17 Aug · Board meeting
May 2016
Feb 2016
Oct 2015
Jul 2015
May 2015
Jan 2015
23 Jan · Board meeting
To consider inter-alia, the unaudited financial results of the Company for the quarter ended December 31, 2014.
Oct 2014
29 Oct · Board meeting
To consider inter-alia, the unaudited financial results of the Company for the quarter ended September 30, 2014.
Sep 2014
29 Sep · Board meeting
To consider declaration of special dividend.
Jul 2014
17 Jul · Board meeting
To consider inter-alia, the unaudited financial results of the Company for the quarter ended June 30, 2014. Further, as per the provisions of the Company's Code for Prevention of Insider Trading, trading window for Designated Employees of the Company will remain closed from July 15, 2014 to July 26, 2014 (both days inclusive).
May 2014
Jan 2014
30 Jan · Board meeting
To consider inter-alia, the unaudited financial results of the Company for the quarter ended December 31, 2013.Further, as per the provisions of the Company s Code for Prevention of Insider Trading, trading window for Designated Employees of the Company will remain closed from January 28, 2014 to February 8, 2014 (both days inclusive).
Dec 2013
5 Dec · Board meeting
To consider declaration of special dividend.
Nov 2013
6 Nov · Board meeting
To consider inter-alia, the unaudited financial results of the Company for the quarter ended September 30, 2013.
Jul 2013
17 Jul · Board meeting
To consider inter-alia, the unaudited financial results of the Company for the quarter ended June 30, 2013.
Apr 2013
18 Apr · Board meeting
To consider inter-alia, the unaudited financial results of the Company for the quarter ended March 31, 2013.
Feb 2013
20 Feb · Board meeting
To consider inter-alia, the audited financial results of the Company for the financial year ended December 31, 2012 and recommendation of dividend, if any.
Oct 2012
15 Oct · Board meeting
To consider inter-alia, the unaudited financial results of the Company for the quarter ended September 30, 2012.
Jul 2012
19 Jul · Board meeting
To consider inter-alia, the unaudited financial results of the Company for the quarter ended June 30, 2012.
Apr 2012
18 Apr · Board meeting
To consider inter-alia, the unaudited financial results of the Company for the quarter ended March 31, 2012.
Feb 2012
21 Feb · Board meeting
To consider inter-alia, the audited financial results of the Company for the financial year ended December 31, 2011 and recommendation of dividend, if any.
Oct 2011
14 Oct · Board meeting
To consider inter-alia, the unaudited financial results of the Company for the quarter ended September 30, 2011.
Jul 2011
19 Jul · Board meeting
To consider inter-alia, the unaudited financial results of the Company for the quarter ended June 30, 2011.
Apr 2011
18 Apr · Board meeting
To consider inter-alia, the unaudited financial results of the Company for the quarter ended March 31, 2011.
Feb 2011
11 Feb · Board meeting
To consider inter-alia, the audited financial results of the Company for the financial year ended December 31, 2010 and recommendation of dividend, if any.
Oct 2010
19 Oct · Board meeting
To consider inter-alia, the unaudited financial results of the Company for the quarter ended September 30, 2010.
Jul 2010
20 Jul · Board meeting
To consider inter-alia, the unaudited financial results of the Company for the quarter ended June 30, 2010.
Apr 2010
15 Apr · Board meeting
Meeting on 22 Apr 2010: “Unaudited Financial Results for the qtr ended March 31, 2010”
Feb 2010
15 Feb · Board meeting
To consider inter-alia, the audited financial results of the Company for the financial year ended December 31, 2009 and recommendation of dividend, if any.